|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Stroke显示文摘 | Geoffrey A Donnan Marc Fisher Malcolm Macleod Stephen M Davis | 2008 | The Lancet . 2008 (9624)2008，，9624： | 2 |
| 2 | Stroke显示文摘 | Geoffrey A Donnan Marc Fisher Malcolm Macleod Stephen M Davis | 2008 | The Lancet2008，，9624： | 2 |
| 3 | Stability of fruit quality traits in diverse watermelon cultivars tested in multiple environments显示文摘Lycopene is a naturally occurring red carotenoid compound that is found in watermelon.Lycopene has antioxidant properties.Lycopene content,sugar content and hollowheart resistance are subject to significant genotype×environment interaction(G×E),which makes breeding for these fruit quality traits difficult.The objectives of this study were to(i)evaluate the influence of years and locations on lycopene content,sugar content and hollowheart resistance for a set of watermelon genotypes,and(ii)identify genotypes with high stability for lycopene,sugar,and hollowheart resistance.A diverse set of 40 genotypes was tested over 3 years and 8 locations across the southern United States in replicated,multi-harvest trials.Lycopene was tested in a subset of 10 genotypes.Data were analyzed using univariate and multivariate stability statistics(BLUP-GGE biplot)using SASGxE and RGxE programs.There were strong effects of environment as well as G×E interaction on watermelon quality traits.On the basis of stability measures,genotypes were classified as stable or unstable for each quality trait.'Crimson Sweet'is an inbred line with high quality trait performance as well as trait stability.'Stone Mountain','Tom Watson','Crimson Sweet'and'Minilee'were among the best genotypes for lycopene content,sugar content and hollowheart resistance.We developed a stability chart based on marketable yield and average ranking generated from different stability measures for yield attributes and quality traits.The chart will assist in choosing parents for improvement of watermelon cultivars.See http://gffzz783b6e01a04243c3hoffbfcoxqbov669v.ffgz.tsg.suse.edu.cn/cucurbit/wmelon/wmelonmain.html. | Mahendra Dia Todd C Wehner Penelope Perkins-Veazie Richard Hassell Daniel S Price George E Boyhan Stephen M Olson Stephen R King Angela R Davis Gregory E Tolla Jerome Bernier Benito Juarez | 2016 | Horticulture Research2016，3，1： | 2 |
| 4 | The incorporation of paper deinking sludge into fiberboard 显示文摘 | Davis Ethan Shaler Stephen M Goodell Barry | 2003 | Forest Products Journal2003，53，1112： | 1 |
| 5 | Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial显示文摘 | Stephen M Davis Geoffrey A Donnan Mark W Parsons Christopher Levi Kenneth S Butcher Andre Peeters P Alan Barber Christopher Bladin Deidre A De Silva Graham Byrnes Jonathan B Chalk John N Fink Thomas E Kimber David Schultz Peter J Hand Judith Frayne Graeme | 2008 | Lancet Neurology2008，，4： | 1 |
| 6 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
| 7 | Towards an integrated global framework to assess the impacts of land use and management change on soil carbon: current capability and future vision显示文摘 | Pete Smith Christian A. Davies Stephen Ogle Giuliana Zanchi Jessica Bellarby Neil Bird Robert M. Boddey Niall P. M c Namara David Powlson Annette Cowie Meine Noordwijk Sarah C. Davis Daniel DE B. Richter Len Kryzanowski Mark T. Wijk Judith Stuart Akira Ki | 2012 | Glob Change Biol2012，，7： | 1 |
| 8 | The incorporation of paper deinking sludge into fiberboard 显示文摘 | Davis Ethan Shaler Stephen M Goodell Barry | 2003 | Forest Products Journal2003，53，1112： | 1 |
| 9 | Rapid analysis of the chemical composition of agricultural fibers using near infrared spectroscopy and pyrolysis molecular beam mass spectrometry 显示文摘 | STEPHEN S Kelley ROGER M Rowell MARK Davis | 2004 | Biomass and Bioenergy2004，27，： | 1 |
| 10 | Peanuts, peanut oil, and fat free peanut flour reduced cardiovascular disease risk factors and the development of atherosclerosis in syrian golden hamsters 显示文摘 | Amanda M Stephens Lisa L Dean Jack P Davis Jason A Osborne Timothy H Sanders | 2010 | Journal of Food Science2010，75，4： | 1 |
| 11 | Arterial compliance adds to conventional risk factors for prediction of angiographic coronary artery disease显示文摘 | David M Herrington Karen Kesler J.H.C Reiber Warren Davis W.Virgil Brown Ronald Helms Stephen M Mallon Jeffrey Raines | 2003 | American Heart Journal2003，，4： | 1 |
| 12 | Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials显示文摘 | Kennedy R Lees Erich Bluhmki Rüdiger von Kummer Thomas G Brott Danilo Toni James C Grotta Gregory W Albers Markku Kaste John R Marler Scott A Hamilton Barbara C Tilley Stephen M Davis Geoffrey A Donnan Werner Hacke | 2010 | The Lancet2010，，9727： | 1 |
| 13 | Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials显示文摘 | Kennedy R Lees Erich Bluhmki Rüdiger von Kummer Thomas G Brott Danilo Toni James C Grotta Gregory W Albers Markku Kaste John R Marler Scott A Hamilton Barbara C Tilley Stephen M Davis Geoffrey A Donnan Werner Hacke | 2010 | The Lancet2010，，9727： | 1 |
| 14 | Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial显示文摘 | Kennedy R Lees Kjell Asplund Antonio Carolei Stephen M Davis Hans-Christoph Diener Markku Kaste Jean-Marc Orgogozo John Whitehead | 2000 | 2000 (9219)2000，，9219： | 1 |
| 15 | Stroke显示文摘 | Geoffrey A Donnan Marc Fisher Malcolm Macleod Stephen M Davis | 2008 | 2008 (9624)2008，，9624： | 1 |
| 16 | Neuroimaging, the ischaemic penumbra, and selection of patients for acute stroke therapy显示文摘 | Geoffrey A Donnan Stephen M Davis | 2002 | Lancet Neurology2002，，7： | 1 |
| 17 | Endovascular thrombectomy for stroke: current best practice and future goals显示文摘Endovascular thrombectomy for large vessel ischaemic stroke substantially reduces disability,with recent positive randomised trials leading to guideline changes worldwide.This review discusses in detail the evidence provided by recent randomised trials and metaanalyses,the remaining areas of uncertainty and the future directions for research.The data from existing trials have demonstrated the robust benefit of endovascular thrombectomy for internal carotid and proximal middle cerebral artery occlusions.Uncertainty remains for more distal occlusions where the efficacy of alteplase is greater,less tissue is at risk and the safety of endovascular procedures is less established.Basilar artery occlusion was excluded from the trials,but with a dire natural history and proof of principle that rapid reperfusion is effective,it seems reasonable to continue treating these patients pending ongoing trial results.There has been no evidence of heterogeneity in treatment effect in clinically defined subgroups by age,indeed,those aged>80 years have at least as great an overall reduction in disability and reduced mortality.Similarly there was no heterogeneity across the range of baseline stroke severities included in the trials.Evidence that routine use of general anaesthesia reduces the benefit of endovascular thrombectomy is increasing and conscious sedation is generally preferred unless severe agitation or airway compromise is present.The impact of time delays has become clearer with description of onset to imaging and imaging to reperfusion epochs.Delays in the onset to imaging reduce the proportion of patients with salvageable brain tissue.However,in the presence of favourable imaging,rapid treatment appears beneficial regardless of the onset to imaging time elapsed.Imaging to reperfusion delays lead to decay in the clinical benefit achieved,particularly in those with less robust collateral flow.The brain imaging options to assess prognosis have various advantages and disadvantages,but whatever strategy is employed must be fast.Ongoing trials are investigating extended time windows,using advanced brain imaging selection.There is also a need for further technical advances to maximise rates of complete reperfusion in the minimum time. | Bruce C V Campbell Geoffrey A Donnan Peter J Mitchell Stephen M Davis | 2016 | Stroke & Vascular Neurology2016，1，1： | 1 |
| 18 | Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial显示文摘 | Roger D James Robert Glynne-Jones Helen M Meadows David Cunningham Arthur Sun Myint Mark P Saunders Timothy Maughan Alec McDonald Sharadah Essapen Martin Leslie Stephen Falk Charles Wilson Simon Gollins Rubina Begum Jonathan Ledermann Latha Kadalayil Davi | 2013 | Lancet Oncology2013，，6： | 1 |
| 19 | 卒中显示文摘卒中是人类的第二大死因,也是导致残疾的主要原因。随着人口的逐渐老龄化,在今后的20年中卒中将给社会发展带来沉重的负担,尤其是对于发展中国家。在过去10年中,卒中的预防和治疗取得了一定的进展。对于急性卒中患者而言,在卒中监护病房接受治疗。在发病3h内静脉输注组织型纤溶酶原激活物或者在发病48h内使用阿司匹林,以及对幕上大面积脑梗死行开瓣减压都是有明确疗效的治疗方法;目前也正在对其他一些治疗方法进行评估。 | Geoffrey A Donnan Marc Fisher Malcolm Macleod Stephen M Davis 程岗(译) | 2008 | 世界临床医学2008，2，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员